Filer Snapshot

Bellevue Group AG

CIK 0001674546. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

49

Latest filing

15 May 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13F-HR for Q1 2026. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Largest parsed holding

VRTX

$304.5M reported value

Open holding

13D/G large stake

VRDN

31 Mar 2026 · 6.6% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Source: SEC Schedule 13D/G

SCHEDULE 13G filed on 15 May 2026 for CIK 0001674546.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Parsed SEC ownership coverage

These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.

13F portfolio$4.2B

Quarterly institutional holdings reported on Form 13F; not total AUM.

Latest reported 13F value

13F
$4.2B

Reported market value from the latest parsed Form 13F information table; this is not total assets under management.

Source: SEC Form 13FScope: U.S.-listed equity holdings

Largest 13F holdings

13F
VRTX ARGX REGN SRRK GILD
+15 moreRVMD IONS ISRG VRDN KRYS CRNX ABT NUVL AMGN BSX ELVN IMCR MDT ALNY RLAY

Largest symbols in the latest parsed Form 13F information table.

Freshness: Latest parsed 13F period

Largest 13F holdings

Largest symbols in the latest parsed Form 13F information table.

VRTX ARGX REGN SRRK GILD RVMD IONS ISRG
+12 moreVRDN KRYS CRNX ABT NUVL AMGN BSX ELVN IMCR MDT ALNY RLAY

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

AGIO IMCR CLDX VRDN JBIO MGNX
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
Theaterstrasse 12, Zurich, CH-8001
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Incorporated in
Switzerland
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Bellevue Group AG

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Quick read

  • Latest parsed 13F shows $4.2B across 155 reported holdings for Q1 2026.
  • Largest parsed 13F holding: VRTX at $304.5M.
  • 5 recent 13D/G stake rows found; top row is VRDN at 6.6% ownership.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio 155 rows

Quarterly institutional portfolio holdings.

Open
13D/G stakes 5 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

Open

Top parsed 13F holdings

Visual share of the latest parsed 13F portfolio. Values are reported market value, not a recommendation.

Q1 2026 - 15 May 2026

Top 5 concentration

26%

Share of latest parsed 13F value represented by the visible holdings below.

Top 5 reported value

$1.09B

Compared with $4.2B total 13F value.

Top 5 net change

+$228.69M

Position-value change inside the visible top holdings only.

13F concentration map

A simple visual split of the latest parsed 13F portfolio.

Largest add: REGN · Largest trim: RVMD

VRTX ARGX REGN SRRK GILD Other holdings

VRTX

7.2%

Vertex Pharmaceuticals Inc

$304.5M

ARGX

5.4%

Argenx Se

$228.57M

REGN

5.1%

Regeneron Pharmaceuticals

$215.31M

SRRK

4.2%

Scholar Rock Hldg Corp

$176.22M

GILD

3.9%

Gilead Sciences Inc

$163.05M

13D/G large-stake context

VRDN

31 Mar 2026 · Common Stock

6.6%

CLDX

31 Mar 2026 · Common Stock

1.5%

JBIO

16 Dec 2025 · Common Stock

6.8%

MGNX

05 Dec 2025 · Common Stock

0%

Latest update

What changed recently for Bellevue Group AG

New filing available

Latest Schedule 13D/G period: 31 Mar 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

15 May 2026

Page type

Filer profile

Latest period

31 Mar 2026

Schedule 13D/G context is visible from filings filed on 15 May 2026.

Benchmark Context

Benchmark context for this company

Bellevue Group AG has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest Schedule 13D/G period: 31 Mar 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

SEC filing record

CIK 0001674546 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
49
First seen
16 May 2016
Latest filing
15 May 2026
Entity
Company

Observed form types

13F-HR SCHEDULE 13G SCHEDULE 13G/A

Latest Filings

Showing the latest 12 of 49 SEC filings for Bellevue Group AG.

SCHEDULE 13G

SCHEDULE 13G filing

Filing date
15 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
15 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
15 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
17 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
06 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
05 Dec 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
14 Nov 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Nov 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
13F-HR

13F-HR filing

Filing date
14 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
07 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
07 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .